<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28852" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Selective Serotonin Reuptake Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chu</surname>
            <given-names>Andrew</given-names>
          </name>
          <aff>HCA University Hospital Tamarac</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Chu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28852.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Selective serotonin reuptake inhibitors (SSRIs) are a class of medications most commonly prescribed to treat depression. They are often used as first-line pharmacotherapy for depression and numerous other psychiatric disorders due to their safety, efficacy, and tolerability. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with depression and other psychiatric disorders for which SSRIs are indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for SSRIs.</p></list-item><list-item><p>Describe the most common adverse effects of SSRIs.</p></list-item><list-item><p>Review the mechanism of action of SSRIs.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team members to improve outcomes for patients receiving SSRIs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28852&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28852">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28852.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Selective serotonin reuptake inhibitors (SSRIs) are a class of medications most commonly prescribed to treat depression. They are often used as first-line pharmacotherapy for depression and numerous other psychiatric disorders due to their safety, efficacy, and tolerability. They are approved for use in both adult and pediatric patients.<xref ref-type="bibr" rid="article-28852.r1">[1]</xref></p>
        <p>The current SSRIs in use in the United States are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluoxetine</p>
          </list-item>
          <list-item>
            <p>Sertraline</p>
          </list-item>
          <list-item>
            <p>Paroxetine</p>
          </list-item>
          <list-item>
            <p>Fluvoxamine</p>
          </list-item>
          <list-item>
            <p>Citalopram</p>
          </list-item>
          <list-item>
            <p>Escitalopram</p>
          </list-item>
          <list-item>
            <p>Vilazodone</p>
          </list-item>
        </list>
        <p>SSRIs currently have FDA labeled indications&#x000a0;to treat the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Major depressive disorder</p>
          </list-item>
          <list-item>
            <p>Generalized anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Bulimia nervosa</p>
          </list-item>
          <list-item>
            <p>Bipolar depression<xref ref-type="bibr" rid="article-28852.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Obsessive-compulsive disorder</p>
          </list-item>
          <list-item>
            <p>Panic disorder</p>
          </list-item>
          <list-item>
            <p>Premenstrual dysphoric disorder</p>
          </list-item>
          <list-item>
            <p>Treatment-resistant depression</p>
          </list-item>
          <list-item>
            <p>Post-traumatic stress disorder</p>
          </list-item>
          <list-item>
            <p>Social anxiety disorder</p>
          </list-item>
        </list>
        <p>Other off-label uses include but are not limited to: Binge eating disorder, Body dysmorphic disorder, fibromyalgia, premature ejaculation, paraphilias, autism, Raynaud phenomenon, and vasomotor symptoms associated with menopause.<xref ref-type="bibr" rid="article-28852.r3">[3]</xref></p>
      </sec>
      <sec id="article-28852.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The therapeutic actions of SSRIs&#x000a0;have their basis on increasing deficient serotonin that researchers postulate as the cause of depression in the monoamine hypothesis. As the name suggests, SSRIs exert action by inhibiting the reuptake of serotonin, thereby increasing serotonin activity. Unlike other classes of antidepressants, SSRIs&#x000a0;have little effect on other neurotransmitters, such as dopamine or norepinephrine. SSRIs also have relatively fewer side effects than TCAs and MAOIs due to fewer effects on adrenergic, cholinergic, and histaminergic receptors.</p>
        <p>SSRIs inhibit the serotonin transporter (SERT) at the presynaptic axon terminal. By&#x000a0;inhibiting&#x000a0;SERT, an increased amount of serotonin (5-hydroxytryptamine or 5HT) remains in the synaptic cleft and can stimulate postsynaptic receptors for a more extended period.<xref ref-type="bibr" rid="article-28852.r4">[4]</xref><xref ref-type="bibr" rid="article-28852.r5">[5]</xref><xref ref-type="bibr" rid="article-28852.r6">[6]</xref></p>
      </sec>
      <sec id="article-28852.s4" sec-type="Administration">
        <title>Administration</title>
        <p>SSRIs are only available orally and come in multiple forms, including tablets, capsules, or liquid suspension/solution. There are currently no parenteral (IV, IM, SubQ), rectal, or other forms of SSRIs. SSRI administration is typically once-daily medication in the morning or nighttime.&#x000a0;Except for vilazodone, SSRIs&#x000a0;may be taken without regard to food. Vilazodone should be administered with food.<xref ref-type="bibr" rid="article-28852.r6">[6]</xref></p>
      </sec>
      <sec id="article-28852.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The popularity and widespread use of SSRIs is due in part to their relatively fewer side effects than prior commonly used antidepressants such as TCAs and MAOIs. SSRIs have little or no effect on dopamine, norepinephrine, histamine, or acetylcholine (except for paroxetine). This characteristic leads to fewer complaints of side effects such as xerostomia, sedation, constipation, urinary retention, and cognitive impairments.<xref ref-type="bibr" rid="article-28852.r7">[7]</xref><xref ref-type="bibr" rid="article-28852.r8">[8]</xref></p>
        <p>Increased tolerability compared to other classes of medications make SSRIs first-line options for their indicated uses. Although relatively safer due to their selectiveness for serotonin, SSRIs are not without risks.&#x000a0;</p>
        <p>In 2004, the FDA issued a black box warning for SSRIs and other antidepressant medications due to a possible increased risk of suicidality among pediatric and young adult (up to age 25) populations. The risk and benefits of initiating SSRI therapy on acutely suicidal patients must be weighed, keeping in mind that depression itself is a large risk factor for suicidality and requires treatment. Common side effects from SSRIs include sexual dysfunction, sleep disturbances, weight changes, anxiety, dizziness, xerostomia, headache, and gastrointestinal distress.<xref ref-type="bibr" rid="article-28852.r9">[9]</xref><xref ref-type="bibr" rid="article-28852.r10">[10]</xref></p>
        <p>SSRIs also have the potential to prolong the&#x000a0;QT interval, which can lead to fatal arrhythmia, torsade de pointes. Citalopram has correlations with a longer QT duration than the other medications in this class.<xref ref-type="bibr" rid="article-28852.r11">[11]</xref><xref ref-type="bibr" rid="article-28852.r12">[12]</xref>&#x000a0;Coagulopathy also correlates with SSRI use.<xref ref-type="bibr" rid="article-28852.r13">[13]</xref>&#x000a0;Although infrequent, as with all medications that increase serotonin activity, it is important to be aware of the risk of serotonin syndrome, particularly when prescribing multiple medications that may have serotonergic effects.</p>
        <p>SSRIs&#x000a0;are metabolized by and have effects on the&#x000a0;cytochrome P450 system. Fluoxetine, paroxetine, sertraline, citalopram, and&#x000a0;escitalopram are inhibitors of CYP2D6. Fluoxetine and fluvoxamine are inhibitors of CYP2C19. Fluvoxamine is an inhibitor of CYP1A2.<xref ref-type="bibr" rid="article-28852.r6">[6]</xref></p>
      </sec>
      <sec id="article-28852.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>SSRIs are contraindicated with the concurrent use of MAOIs, linezolid, and other medications that increase serotonin levels and could put patients at risk for life-threatening serotonin syndrome.</p>
        <p>Paroxetine is contraindicated in pregnancy and is classified as category D/X due to its teratogenic effects in causing cardiovascular defects, specifically cardiac malformations if prescribed in the first trimester.<xref ref-type="bibr" rid="article-28852.r14">[14]</xref></p>
      </sec>
      <sec id="article-28852.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The effect of SSRIs may take up to 6 weeks before the patients feel the effects of treatment.<xref ref-type="bibr" rid="article-28852.r15">[15]</xref> If patients tolerate the current dose well, the clinician can consider an increase in dosage after several weeks.</p>
        <p>All patients under the age of 25 should be continually assessed for suicidal ideation and other unusual behaviors, as highlighted in the FDA black box warning for all SSRI medications.</p>
        <p>For patients with cardiac risk factors, an EKG may be an option to monitor for QT prolongation and arrhythmias.</p>
        <p>Weight should be regularly measured and tracked to determine any adverse metabolic changes, and vital signs should also be regularly measured to monitor for adverse changes.</p>
        <p>Anxiety, insomnia, and sexual dysfunction (delayed ejaculation, decreased sexual desire, and anorgasmia) require regular assessment.</p>
      </sec>
      <sec id="article-28852.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>SSRI overdose is relatively infrequent due to their increased safety profile and tolerability compared to other classes of antidepressants.&#x000a0;SSRI overdoses are rarely fatal and usually do not have serious consequences.&#x000a0;Out of all the SSRIs, citalopram and escitalopram are more likely to cause overdose due to differences in their structures. Citalopram and escitalopram have an increased risk of&#x000a0;cardiotoxicity due to QT prolongation, which can progress to serious arrhythmias such as Torsades.</p>
        <p>Serotonin syndrome is a life-threatening consequence of increased serotonergic activity. It can result from overdosing on SSRIs or from combining multiple medications that increase serotonin levels. Serotonin syndrome is characterized by mental status changes, autonomic dysfunction, and dystonias. Findings may include agitation, tachycardia, hypertension, hyperthermia,&#x000a0;hyperreflexia, tremor, nausea, vomiting, and clonus.<xref ref-type="bibr" rid="article-28852.r16">[16]</xref>&#x000a0;Serotonin syndrome may present similarly to neuroleptic malignant syndrome and malignant hyperthermia. This is&#x000a0;especially important to keep in mind since commonly prescribed psychiatric medications can cause both serotonin syndrome and neuroleptic malignant syndrome. In general, serotonin syndrome is distinguishable by taking a thorough history. Serotonin syndrome also has a rapid onset and resolution. There is no definitive treatment for serotonin syndrome aside from discontinuing the offending agent, supportive measures, and benzodiazepines for agitation. Cyproheptadine has shown some success in several small studies and case reports for patients who do not respond to initial treatment.</p>
      </sec>
      <sec id="article-28852.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>SSRIs are currently some of the most commonly prescribed medications. They are used to treat numerous conditions and may be used in many settings, not just in primary care or psychiatry.&#x000a0;Patients may be on these medications for the long term. Therefore, it is essential to have accurate medication reconciliation by the entire interprofessional team, including clinicians, pharmacists, nursing staff, and other health professionals. This interprofessional approach to SSRI therapy will lead to better patient outcomes with fewer adverse events. [Level 5]</p>
        <p>Serotonin syndrome is important to keep in mind due to the widespread use of SSRIs. If suspected by a triage nurse in an emergency setting, it is important that the emergency medicine physician immediately begin supportive treatment.&#x000a0;Coordinating with the intensivist and ICU nursing staff may also be required as&#x000a0;treatment&#x000a0;may require immediate sedation and intubation. A neurologist may also be important for ongoing care. Although there is no definitive treatment for serotonin syndrome, researchers have trialed cyproheptadine with some success in small studies and case reports.<xref ref-type="bibr" rid="article-28852.r17">[17]</xref><xref ref-type="bibr" rid="article-28852.r18">[18]</xref><xref ref-type="bibr" rid="article-28852.r19">[19]</xref><xref ref-type="bibr" rid="article-28852.r20">[20]</xref>&#x000a0;[Level 4]</p>
      </sec>
      <sec id="article-28852.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28852&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28852">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28852/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28852">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28852.s11">
        <title>References</title>
        <ref id="article-28852.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeLucia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kelsberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Safranek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Which SSRIs most effectively treat depression in adolescents?</article-title>
            <source>J Fam Pract</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>632</fpage>
            <page-range>632-4</page-range>
            <pub-id pub-id-type="pmid">27672691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antosik-W&#x000f3;jci&#x00144;ska</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Stefanowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x0015a;wi&#x00119;cicki</surname>
                <given-names>&#x00141;</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of antidepressant's use in the treatment of depressive episodes in bipolar disorder - review of research.</article-title>
            <source>Psychiatr Pol</source>
            <year>2015</year>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>1223</fpage>
            <page-range>1223-39</page-range>
            <pub-id pub-id-type="pmid">26909398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coleiro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>1038</fpage>
            <page-range>1038-43</page-range>
            <pub-id pub-id-type="pmid">11561116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feighner</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of antidepressant medications.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1999</year>
            <volume>60 Suppl 4</volume>
            <fpage>4</fpage>
            <page-range>4-11; discussion 12-3</page-range>
            <pub-id pub-id-type="pmid">10086478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xue</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.</article-title>
            <source>Phys Chem Chem Phys</source>
            <year>2016</year>
            <month>Jan</month>
            <day>28</day>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>3260</fpage>
            <page-range>3260-71</page-range>
            <pub-id pub-id-type="pmid">26745505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preskorn</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1997</year>
            <volume>32 Suppl 1</volume>
            <fpage>1</fpage>
            <page-range>1-21</page-range>
            <pub-id pub-id-type="pmid">9068931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschfeld</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1999</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>326</fpage>
            <page-range>326-35</page-range>
            <pub-id pub-id-type="pmid">10362442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kocsis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs.</article-title>
            <source>Evid Based Ment Health</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>82</fpage>
            <pub-id pub-id-type="pmid">23604275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gourion</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Antidepressant and tolerance: Determinants and management of major side effects].</article-title>
            <source>Encephale</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>553</fpage>
            <page-range>553-561</page-range>
            <pub-id pub-id-type="pmid">27423475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hunkeler</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ming</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Fireman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Markson</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>959</fpage>
            <page-range>959-65</page-range>
            <pub-id pub-id-type="pmid">15291685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funk</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bostwick</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>A comparison of the risk of QT prolongation among SSRIs.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1330</fpage>
            <page-range>1330-41</page-range>
            <pub-id pub-id-type="pmid">24259697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ruskin</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2014</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>e441</fpage>
            <page-range>e441-9</page-range>
            <pub-id pub-id-type="pmid">24922496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laporte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chapelle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caillet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Beyens</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Bellet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delavenne</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mismetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bertoletti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.</article-title>
            <source>Pharmacol Res</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>118</volume>
            <fpage>19</fpage>
            <page-range>19-32</page-range>
            <pub-id pub-id-type="pmid">27521835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Susser</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sansone</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors for depression in pregnancy.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>215</volume>
            <issue>6</issue>
            <fpage>722</fpage>
            <page-range>722-730</page-range>
            <pub-id pub-id-type="pmid">27430585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Freemantle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bhagwagar</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>11</issue>
            <fpage>1217</fpage>
            <page-range>1217-23</page-range>
            <pub-id pub-id-type="pmid">17088502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wilborn</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>2012</year>
            <month>May</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-62</page-range>
            <pub-id pub-id-type="pmid">22563571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stearman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the serotonin syndrome with cyproheptadine.</article-title>
            <source>J Emerg Med</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>615</fpage>
            <page-range>615-9</page-range>
            <pub-id pub-id-type="pmid">9696181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baigel</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Cyproheptadine and the treatment of an unconscious patient with the serotonin syndrome.</article-title>
            <source>Eur J Anaesthesiol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>586</fpage>
            <page-range>586-8</page-range>
            <pub-id pub-id-type="pmid">12884999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>BZ</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>325</fpage>
            <page-range>325-7</page-range>
            <pub-id pub-id-type="pmid">10532660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28852.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDaniel</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: early management with cyproheptadine.</article-title>
            <source>Ann Pharmacother</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>35</volume>
            <issue>7-8</issue>
            <fpage>870</fpage>
            <page-range>870-3</page-range>
            <pub-id pub-id-type="pmid">11485136</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
